Literature DB >> 23762891

Influenza infection screening tools fail to accurately predict influenza status for patients during pandemic H1N1 influenza season.

Sunita Mulpuru1, Virginia R Roth, Nadine Lawrence, Alan J Forster.   

Abstract

BACKGROUND: Following the severe acute respiratory syndrome outbreak in 2003, hospitals have been mandated to use infection screening questionnaires to determine which patients have infectious respiratory illness and, therefore, require isolation precautions. Despite widespread use of symptom-based screening tools in Ontario, there are no data supporting the accuracy of these screening tools in hospitalized patients.
OBJECTIVE: To measure the performance characteristics of infection screening tools used during the H1N1 influenza season.
METHODS: The present retrospective cohort study was conducted at The Ottawa Hospital (Ottawa, Ontario) between October and December, 2009. Consecutive inpatients admitted from the emergency department were included if they were ≥18 years of age, underwent a screening tool assessment at presentation and had a most responsible diagnosis that was cardiac, respiratory or infectious. The gold-standard outcome was laboratory diagnosis of influenza.
RESULTS: The prevalence of laboratory-confirmed influenza was 23.5%. The sensitivity and specificity of the febrile respiratory illness screening tool were 74.5% (95% CI 60.5% to 84.8%) and 32.7% (95% CI 25.8% to 40.5%), respectively. The sensitivity and specificity of the influenza-like illness screening tool were 75.6% (95% CI 61.3% to 85.8%) and 46.3% (95% CI 38.2% to 54.7%), respectively.
CONCLUSIONS: The febrile respiratory illness screening tool missed 26% of active influenza cases, while 67% of noninfluenza patients were unnecessarily placed under respiratory isolation. Results of the present study suggest that infection-control practitioners should re-evaluate their strategy of screening patients at admission for contagious respiratory illness using symptom- and sign-based tests. Future efforts should focus on the derivation and validation of clinical decision rules that combine clinical features with laboratory tests.

Entities:  

Mesh:

Year:  2013        PMID: 23762891      PMCID: PMC3814272          DOI: 10.1155/2013/762140

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  21 in total

1.  Validity of information on comorbidity derived rom ICD-9-CCM administrative data.

Authors:  Hude Quan; Gerry A Parsons; William A Ghali
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  The limitations of point of care testing for pandemic influenza: what clinicians and public health professionals need to know.

Authors:  Todd F Hatchette; Nathalie Bastien; Jody Berry; Tim F Booth; Max Chernesky; Michel Couillard; Steven Drews; Anthony Ebsworth; Margaret Fearon; Kevin Fonseca; Julie Fox; Jean-Nicolas Gagnon; Steven Guercio; Greg Horsman; Cathy Jorowski; Theodore Kuschak; Yan Li; Anna Majury; Martin Petric; Sam Ratnam; Marek Smieja; Paul Van Caeseele
Journal:  Can J Public Health       Date:  2009 May-Jun

3.  Diagnosis of 2009 pandemic influenza A (pH1N1) and seasonal influenza using rapid influenza antigen tests, San Antonio, Texas, April-June 2009.

Authors:  Pauline M Lucas; Oliver W Morgan; Thomas F Gibbons; Alicia C Guerrero; Genny M Maupin; Jenny L Butler; Linda C Canas; Vincent P Fonseca; Sonja J Olsen; Victor H MacIntosh
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

4.  Performance of five FDA-approved rapid antigen tests in the detection of 2009 H1N1 influenza A virus.

Authors:  Deena E Sutter; Sue A Worthy; Donna M Hensley; Ashley M Maranich; Donna M Dolan; Gerald W Fischer; Luke T Daum
Journal:  J Med Virol       Date:  2012-11       Impact factor: 2.327

5.  Predicting influenza infections during epidemics with use of a clinical case definition.

Authors:  G Boivin; I Hardy; G Tellier; J Maziade
Journal:  Clin Infect Dis       Date:  2000-11-06       Impact factor: 9.079

6.  Clinical signs and symptoms predicting influenza infection.

Authors:  A S Monto; S Gravenstein; M Elliott; M Colopy; J Schweinle
Journal:  Arch Intern Med       Date:  2000-11-27

Review 7.  A systematic review of clinical decision rules for the diagnosis of influenza.

Authors:  Mark H Ebell; Anna Afonso
Journal:  Ann Fam Med       Date:  2011 Jan-Feb       Impact factor: 5.166

8.  Symptoms of influenza virus infection in hospitalized patients.

Authors:  C van den Dool; E Hak; J Wallinga; A M van Loon; J W J Lammers; M J M Bonten
Journal:  Infect Control Hosp Epidemiol       Date:  2008-04       Impact factor: 3.254

9.  Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults.

Authors:  Thomas Bewick; Puja Myles; Sonia Greenwood; Jonathan S Nguyen-Van-Tam; Stephen J Brett; Malcolm G Semple; Peter J Openshaw; Barbara Bannister; Robert C Read; Bruce L Taylor; Jim McMenamin; Joanne E Enstone; Karl G Nicholson; Wei Shen Lim
Journal:  Thorax       Date:  2011-01-20       Impact factor: 9.139

Review 10.  Adverse effects of isolation in hospitalised patients: a systematic review.

Authors:  C Abad; A Fearday; N Safdar
Journal:  J Hosp Infect       Date:  2010-10       Impact factor: 3.926

View more
  3 in total

1.  Predictors of Influenza Diagnosis Among Patients With Laboratory-Confirmed Influenza.

Authors:  Marc R Miller; Timothy R Peters; Cynthia K Suerken; Beverly M Snively; Katherine A Poehling
Journal:  J Infect Dis       Date:  2015-05-04       Impact factor: 5.226

2.  Influenza-attributable burden in United Kingdom primary care.

Authors:  D M Fleming; R J Taylor; F Haguinet; C Schuck-Paim; J Logie; D J Webb; R L Lustig; G Matias
Journal:  Epidemiol Infect       Date:  2015-07-13       Impact factor: 2.451

Review 3.  Is influenza-like illness a useful concept and an appropriate test of influenza vaccine effectiveness?

Authors:  Roger E Thomas
Journal:  Vaccine       Date:  2014-02-28       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.